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Abbreviations 
 
Peripheral Nervous System (PNS) 
Central Nervous System (CNS) 
Schmidt-Lanterman incisure (SLIs) 
Myelin Protein Zero (MPZ or MP0) 
Myelin Proteolipid (PLP) 
Myelin-associated glycoprotein (MAG) 
Myelin Basic Protein (MBP) 
Myelin Associated Glycoprotein (MAG) 
Peripheral Myelin Protein (PMP22) 
Fatty Acid Binding Proteins (FABP) 
Charcot-Marie-Tooth type 1B (CMT1B) 
Charcot-Marie-Tooth (CMT) 
Congenital Disorders of Glycosylation (CDG) 
Phosphomutase-2 (PMM2) 
Diethylaminoethanol–High Performance Liquid Chromatography (DEAE-
HPLC) 
Human Natural Killer-1 (HNK-1) 
Matrix-Assisted Laser Desorption/Ionization Time-of-flight Mass 
Spectrometry (MALDI-TOF) 
Mass Spectrometry (MS) 
Mass/Charge ratio (m/z) 
Liquid Chromatography–Mass Spectrometry (LC-MS) 
Protease Inhibitor Cocktails (PIC) 
Ammonium Hydrogen Carbonate (AMBIC) 
3,4-diamino-benzophenone (DABP) 
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Introduction 
1.1 Myelin 
 
The myelin sheath is a greatly extended and modified plasma membrane 
wrapped around the nerve axon in a spiral fashion. Myelin facilitates 
saltatory transmission of electrical impulses along axons (Raine CS 1984). 
The most important function of myelin is to increase the conduction 
velocity of the axon without increasing axon diameter. Myelin works like 
an electrical insulator, allowing the nerve impulses to jump between 
unmyelinated regions of the axon. These regions, called nodes of Ranvier, 
are located between the myelinated area and have very similar structure in 
CNS (Central Nervous System) and PNS (Peripheral Nervous System). In 
myelinated axon, the node of Ranvier is the location of sodium channel. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. General representation of myelin saltatory impulse. 
 
The myelin sheath has two distinct regions, compact myelin and non-
compact myelin. Non-compact myelin contains cytoplasm and is thought to 
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be involved in cell signaling, transport and the physiological homeostasis of 
myelin. Non-compact myelin is composed by Schmidt-Lanterman incisures 
(SLI), paranodal loops and outer mesaxons. 
SLIs are small pockets containing residual cytoplasm, which are formed 
during the myelination process. These clefts provide communication 
channels between layers by connecting the Schwann cell and the deepest 
layer of the myelin sheath (Small J et al. 1987). 
The paranodal loops flank the nodes of Ranvier and are rich in cellular 
junctions that provide a barrier between the extracellular space and the 
periaxonal space (Spiegel I et al. 2002). In the PNS the myelin membranes 
originate from the Schwann cells, while in the CNS they are formed by 
oligodendrocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Myelinated Axon EM. This electron microscopy image shows 
a cross section of a myelinated nerve in the peripheral nervous system. The 
Schwann cell wraps around the axon to envelop it in a myelin sheath that 
functions as an electrical insulator. (http://medcell.med.yale.edu/histology) 
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Schwann cells derive from the neural crest. During development, they 
undergo several differentiation steps, from the immature stage to the non-
myelinating, promyelinating and actively myelinating cells. Moreover, after 
nerve injury, myelinating cells can convert to a highly specialized cell (the 
repair Schwann cell) that is essential for nerve regeneration (Arthur-Farraj 
PJ et al. 2012). 
Characteristic gene expression changes accompany each stage of 
Schwann cell development and various transcription factors are up- and 
down-regulated to coordinate their maturation from neural crest cells to 
mature myelinating or non-myelinating cells. The genes mainly involved in 
the differentiation of the Schwann cells are sox10, krox20 (Egr2) and oct6. 
Sox10 is the first gene activated during the detachment from the neural crest 
and stay up-regulated in migrating cells and immature cells (Scherer SS et 
al. 2008). Oct6 is activated in promyelinating cells and together with sox10 
and krox20 support the final differentiation in Schwann cells. Sox10 and 
krox20 regulation will be also necessary for the maintaining of Schwann 
cell functions and properties (Scherer SS et al. 2008). 
The most important protein up-regulated during this promyelinating 
pathway is Myelin Protein Zero (MPZ). Consequently, MPZ is also the 
most abundant proteins in compact PNS myelin (Quarles RH et al. 2006). 
The importance of proper PNS myelin function is highlighted by the 
devastating effects of demyelination in several diseases, such as acquired 
neuropathies or in genetic syndromes (Scherer SS et al. 2008). 
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Figure 3. Main genes involved in the differentiation of the Schwann 
cells and the oligodendrocytes. (Emery B et al. 2013) 
 
 
 
 
 
9 
 
1.1.1 Myelin composition 
Myelin is composed of roughly 70% lipid and 30% proteins; while lipid 
composition is similar, there are important differences between CNS and 
PNS myelin proteins. While some are found in both systems, such as 
Myelin Associated Glycoprotein (MAG) and Myelin Basic Protein (MBP), 
others are more specific for PNS myelin, as Myelin Protein Zero (MPZ or 
P0) and Peripheral Myelin Protein (PMP22) (Quarles RH et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. SDS-Polyacrilamide gel electrophoresis of myelin proteins. A) 
Human PNS myelin, B) Human CNS myelin C) Rat PNS myelin D) Rat 
CNS myelin.  There is a high similarity in the PNS, where only MPZ is 
expressed at high level. (Quarles RH et al. 2006)  
 
 
The MBPs are proteins localized at the plasma membrane; evidences 
suggest a homodimer structure that may have an important role in 
stabilizing myelin. The MBP genes can undergo alternative splicing and, as 
a result, there are different isoforms, which the most abundant is the 18.5 
kDa form (Quarles RH et al. 2006). 
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PMP-22 is a glycoprotein with four hydrophobic transmembrane 
domains: it is found in the compact myelin and it characterised by a single 
N-glycosylation site. It is less abundant than MPZ and is not nerve specific 
because it can be found in many other tissues. It is present in a small 
amount in the plasma membranes of both myelinating and nonmyelinating 
Schwann cells, suggesting a role in maintenance and assemblage of myelin 
structure (Quarles RH et al. 2006). 
MAG is situated in the periaxonal membrane of myelin and in the 
Schwann cell membranes of the Schmidt-Lanterman incisures. MAG 
control adhesion and signalling between myelinating cells and axons and 
maintains a defined spacing between the innermost myelin surface and the 
axon surface (Pronker MF et al. 2016). 
P2 protein is a positively 15 kDa charged protein, member of 
cytoplasmic Fatty Acid Binding Proteins (FABP). Larger amounts of P2 
protein are found in the compact myelin (Kirschner DA et al. 1992), but 
there is no experimental evidence of its function and role. P2 have a high 
homology with the proteins that interact with membrane lipid suggesting its 
involvement in the assemblage of the myelin sheath (Quarles RH et al. 
2006). 
 
 
 
 
 
 
 
 
11 
 
1.1.2 MPZ 
 
The major difference on the protein composition between CNS and PNS 
is that MPZ replace almost completely PLP as the most abundant protein. 
These proteins may have a similar role in the formation and homeostasis of 
myelin, but sequence and post-translational modifications are very 
different. 
 
Figure 5. MPZ (P0) and PLP. Copyright © 2012, American Society for 
Neurochemistry 
 
Previous studies indicated that MPZ is the major component of PNS 
myelin, accounting for more than 60% of total proteins (Eichberg J 2002). 
However, a recent proteomic analysis of PNS myelin re-evaluated these 
estimates, revealing that MPZ represents 21% of total proteins, followed by 
periaxin (16%) and myelin basic protein (MBP, 8%) (Patzig J et al. 2011). 
MPZ is a transmembrane glycoprotein of 25 kD expressed by Schwann 
cell. MPZ has an extracellular Ig-like domain, which contains a single site 
for N-glycosylation and the glycans at this site are very heterogeneous. The 
intracellular domain can undergo through other post-translational 
modification that includes phosphorylation and acylation (D'Urso et al. 
1990; Eichberg & Iyer, 1996). 
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Evidence seems to suggest that the Ig-like extracellular hydrophobic 
domain (Figure 6.) ensure the right formation of the multi-lamellar myelin 
sheath and myelin compaction through homophilic binding (Kirschner, DA 
2004).    
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Crystal structure of the extracellular domain of human MPZ 
protein https://www.ebi.ac.uk/pdbe/entry/pdb/3oai/citations 
 
The N-glycans attached to the extracellular domains of MPZ could have 
different roles. Glycans, together with the large Ig-like domains, may be 
responsible for the wider space between extracellular surfaces in PNS 
myelin or, as some studies suggest, may have an important role in the 
interaction among the adjoining MPZ molecules (Shapiro et al. 1996). 
Autosomal dominant mutations of MPZ lead to the development of 
Charcot-Marie-Tooth type 1B (CMT1B) in patients, who develop peripheral 
neuropathies of different gravity and age of onset, depending on the 
mutation involved (Scherer SS et al. 2008). 
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1.2 Myelin Glycosylation 
 
1.2.1 Glycosylation 
 
Glycosylation is a multi-step process (nucleotide sugar biosynthesis and 
transport, sugar transfer and glycoprotein secretion) that, if altered, may 
compromise the function of the modified proteins. Proteins with altered 
glycosylation can have a gain/loss of function and lead to a pathogenic 
condition. 
N-glycosylation is a particular modification in which a glycan is attached 
to proteins at asparagine residue by an N-glycosidic bond. In eukaryotes, 
the first sugar bound to the protein is N-acetylglucosamine (GlcNAc). N-
glycans have a high diversity and they have important functions, like 
quality control of protein folding, cell adhesion and protein interactions 
(Stanley P et al. 2009). 
 
 
 
 
 
 
 
 
 
 
Figure 7. Representation of different type of N-glycans. In this figure 
can be notice the common N-Glycans core composed by GlcNAc2-Man3. 
(Essentials of Glycobiology, Chapter 9 fig 1) 
 
N-glycans are added to membrane and secreted proteins at a particular 
consensus sequence that is Asn-X-Ser/Thr. The importance of this 
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modification is given by the fact that 70% of proteins have the consensus 
sequence for N-glycosylation and 70% of these sequences are N-
glycosylated. Three types of N-linked structures are present: i) the 
oligomannose type, which contains only mannose residues beside the 
chitobiose core; ii) the complex type, in which both antennae are 
substituted, generally by lactosamine units; and iii) the hybrid type, which 
presents both type of structures on the two antennae, as shown in Figure 7. 
The complex types can harbour different numbers of antennae, which 
generally contain a terminal sialic acid or more complex structure, such as 
antigens of the Lewis system (Stanley P et al. 2009). 
For the study of N-glycans, it is possible to use some enzyme that release 
the sugar chains. Peptide N-Glycosidase-F (PNGaseF) for example, is a 
bacterial enzyme that cleaves the N-glycosydic bond, thus releasing the 
complete glycan. Endoglycosidase H, cleave the O-glycosydic bond 
between the two core GlcNAc residues (Stanley P et al. 2009). 
In O-glycosylation, glycans are attached to a Serine or Threonine 
residue. This modification is typical of mucin-type glycoproteins, in which 
the glycan portion is essential for their function.  However, this 
modification can be found in many different glycoproteins and the glycan 
chains may highly variable. Proteins can attach either a single GalNAc or 
more than 20 sugar residues, as for instance it occurs for the antigens of the 
ABO blood group (Stanley P et al. 2009). There is not a particular 
consensus sequence for O-glycosylation because the first enzymes involved 
in this pathway (the GalNAc transferases) have more isoforms, which 
recognise different substrates. In this case, recognition is due to the 
tridimensional structure of the polypeptide chain. 
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1.2.2 Congenital Disorders of Glycosylation 
 
The Congenital Disorders of Glycosylation (CDG) are a group of genetic 
disease with an autosomal recessive inheritance caused by a defect in 
glycosylation (Freeze HH et al. 2017). 
CDG are divided in two main groups: CDG1 (Figure 8) and CDG2 
(Figure 9). The first one is characterised by a general hypoglycosylation 
status of proteins due to defects on glycan precursor assemblage. The 
second one has an alteration of glycan composition because mutations are 
situated on genes codifying glycosyltransferases and membrane-nucleotide 
sugar transporters. CDG-N-linked are disorders caused by the defective 
synthesis of N-glycans with an early infancy outbreak. 
Because the glycosylation has effect on many proteins that have a 
different function, CDGs have disparate symptoms. In the 70% of all 
known case (CDG-1A), the defective enzyme is the phosphomannomutase-
2 (PMM2). The disease causes a developmental delay that can lead to 
mental disability. It impairs the ability to both move and coordinate the 
movements. Approximately 20% of cases with the disease die within the 
first year of life. CDG-1A patients have a decrease in motor-nerve 
conduction velocity, but less noticeable effects on sensory nerve 
conduction, indicating the presence of a PNS neuropathy (Pascual-
Castroviejo I et al. 2006) and suggesting an important role of N-linked 
glycans in PNS physiology. 
Mutations also in other genes involved in glycan biosynthesis have been 
also related to the onset of PNS neurodegenerative diseases. For instance, 
GlcNAcT-I inactivation, a Golgi glycosyltransferase essential for the 
biosynthesis of hybrid and complex N-glycans, was found to be responsible 
for severe neuropathies leading to tremors and paralysis (Scott H et al. 
2014; Ye Z et al. 2004). 
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The number of mutations affecting the genes involved in the glycan 
formation is constantly increasing, thus studies of CDG patients can also 
provide useful information about the role of specific glycans in the PNS 
myelin function. 
 
 
Figure 8. Location of defects in type I congenital disorders of 
glycosylation (CDG-I) (Freeze HH et al. 2009) 
 
Figure 9. Location of defects in type II congenital disorders of 
glycosylation (CDG-II) (Freeze HH et al. 2009) 
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1.2.3 MPZ N-glycosylation 
  
As indicated above, MPZ exhibits a single N-linked glycosylation site 
(N122) and it represents the most abundant protein carrying N-linked 
glycans in PNS myelin (Figure 10). Thus, its glycans accounts for the 
majority myelin glycosylation. Recently, several spontaneous human 
mutations that modify the glycosylation status of MPZ have been identified, 
either by abrogating the single glycosylation site or by adding new sites for 
N-linked glycosylation (Prada V et al. 2012; Grandis M et al. 2008). 
Altogether, clinical data from patients suggest that MPZ glycosylation 
status is important to maintain correct myelin function in PNS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Representation of MPZ.  Mutations highlighted in different 
colour lead to different form of CMT. (Shy ME et al. 2004)  
 
These results are also confirmed by in vitro experiments, which 
demonstrated that glycosylation is essential for the adhesive properties of 
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MPZ (Filbin MT et al. 2007). Recent evidences have demonstrated that in 
mice loss of sulfatation of N-linked glycans induces abnormal myelination 
and axonal degeneration of PNS (Yoshimura T et al. 2017). 
Occurrence of age-dependent alterations in MPZ glycans in the 
peripheral nerve and mammalian spinal cord have been reported, suggesting 
that the glycan heterogeneity might be regulated by alterations in 
physiological conditions, although details of the structural changes of the 
carbohydrate chains have not been elucidated yet (Sato Y et al. 2000, 1999). 
Interestingly, rat MPZ oligosaccharides were reported to change during 
development, with a prevalence of endo-H resistant N-linked glycans after 
birth, which are converted to endo-H sensitive glycans in adult animals 
(Brunden KR 1992). The endo-H sensitive glycans were suggested to be of 
hybrid type, due to their inability to interact with Galanthus nivalis 
agglutinin (Brunden KR 1992). Moreover, significant alterations in MPZ 
glycan structures have been reported after rat nerve resection or crushing 
(Rotenstein L et al. 2008).   
Detailed structures of N-linked glycans of MPZ were recently obtained 
by mass spectrometry, from shark, frog and bovine myelin (Rotenstein L et 
al. 2008; Xie B et al. 2007; Gallego RG 2001). Very recently, N-glycan 
structures were obtained also for rodents and porcine PNS myelin using 
DEAE-HPLC (Diethylaminoethanol–High Performance Liquid 
Chromatography) (Yoshimura T et al. 2017). The results pointed out 
important differences among evolutionary distant species.  
Oligosaccharides from bovine and porcine myelin are characterized by the 
presence of the HNK-1 (Human Natural Killer-1) and 6-O-sulfosialyl-
Lewis X epitopes, together with other unusual sulfated structures 
(Yoshimura T et al. 2017; Voshol H 1996). HNK-1 is also the antigen 
recognized by auto-antibodies in some types of acquired human 
autoimmune neuropathies (Burger D et al.1992, 1990) (Figure 11). 
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Figure 11. Representation of the HNK-1 epitope. GlcNAc-Gal-GlcA-
SO3- (Drawn with Glycoworkbench) 
 
HNK-1 has been reported in PNS myelin of mouse origin, where it 
seems to be restricted only to myelin surrounding motor fibers and not 
present in sensory nerves (Löw K et al. 1994), even if its presence has not 
been confirmed (Yoshimura T et al. 2017). Conversely, antibodies 
recognizing this epitope are not able to stain both motor and sensitive fibers 
in rat PNS (Martini R 1998). These findings indicate that HNK-1 can have 
a different role depending on localization and that important differences 
exist between related species, posing questions about the function of this 
structure in myelin. Moreover, HNK-1 epitope also showed a 
developmental regulation and a different localization between region of 
compact and non-compact paranodal myelin (Field MC. et al. 1992). 
As reported above, several studies have suggested or clearly identified 
N-linked hybrid structures as major component in adult compact myelin 
from different species. The presence of hybrid structure also on human 
myelin is not clear, since one report indicated the presence of complex type 
N-linked glycans only (Burger D et al. 1992), while a second report 
suggested the presence of hybrid structures (Field MC et al. 1992). 
However, a detailed structural analysis is missing for human PNS myelin. 
Another important issue has been raised by the results of Fasano and co-
workers, who analysed N-linked glycans from bovine MPZ purified from 
lipid rafts and in non-raft regions (Fasano A et al. 2008). A prevalence of 
hybrid oligosaccharides was observed in MPZ from lipid rafts, suggesting a 
role for this type of structures in MPZ targeting to specific membrane sites 
(Fasano A et al. 2008). Although myelin is a membrane characterized by 
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very specialized regions, the mechanisms that control protein targeting are 
not fully understood. Indeed, the D61N missense mutation of MPZ, which 
leads to a severe CMT1B syndrome and is characterized by the presence of 
an extra-site for N-linked glycosylation, also impairs intracellular 
trafficking of the protein, suggesting that glycosylation can affect MPZ 
localization (Prada V. et al. 2012). 
1.2.4 Charcot-Marie Tooth diseases 
Charcot-Marie-Tooth (CMT) disease comprises a large group of 
progressive disorders that affect peripheral nerves, due to mutations in 
many different genes, mostly inherited in an autosomal dominant pattern.  
CMT disease is the most common inherited disorder that involves the PNS 
and affects approximately 1 in 2,500 people. It concerns 50,000 people in 
the European Union and probably >2.6 million worldwide. CMT remains 
incurable and only supportive care is presently available (Pareyson D et al. 
2017). It is characterized by degeneration of both myelin sheaths and axons 
of peripheral nerves, presenting a wide spectrum of severity of symptoms 
and anatomopathological findings (Pareyson D. et al. 2017). 
CMT1 represent about 60% of patients who have demyelinating CMT. 
CMT1 is characterised by a slow nerve conduction and it is caused by 
mutations in genes expressed in myelinating Schwann cells. CMT1A is 
often caused by the duplication of PMP22 gene and usually patients present 
the “classical CMT phenotype”. The clinical onset is in the first 20 years; 
the main symptom is represented by difficulty on walking, caused by 
deformity of the lower limb. CMT1B accounts for 10% of total CMT1 
diseases and it is caused by over 200 mutations in the MPZ gene. (Brennan 
KM et.al 2015). 
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CMT2 is clinically similar to CMT1, has relatively normal nerve 
conduction velocities with evidence of axonal degeneration. It is 
characterized by muscular atrophy and bland sensory loss. There are several 
subtypes with a common clinical phenotype that can be distinguished only 
by studying gene mutation (Bird TD et al. 1998). 
CMT4 is autosomal recessive demyelinating CMT1 like, characterized 
by an early outbreak in the first years of life. It is a severe neuropathy, 
which cause spinal deformities and disability.  (Brennan KM et.al 2015). 
Several mouse transgenic models mimicking CMTs have been 
developed, representing powerful tools to study the molecular mechanisms 
at the basis of the disease and to develop possible therapeutic strategies. 
Table 1 reports a summary of the most frequent types of CMT diseases, 
including the mutated gene and the corresponding phenotype. 
 
Table 1. Chart showing CMT mutation and phenotype (Brennan KM et 
al. 2015) 
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1.3 Glycans structural analysis 
 
1.3.1 Glycans and sugars derivatization 
 
Sugar have a high number of functional groups, different tautomeric 
form and some of them are very labile, so glycans analysis can be difficult. 
For this reason, glycans usually undergo through different modification 
before being analysed. There are a lot of possible modification as reported 
in Table 2 and each has its own advantages/drawbacks. Therefore, it is 
important to choose the derivatization method that suits best to the analysis. 
The alditol acetate procedure is a good method for sugar composition 
analysis of glycans by GC-MS and it consists in release of monosaccharides 
by acid hydrolysis followed by the reduction of the aldehyde or ketone 
group of the sugar and the subsequent acetylation of every hydroxyl group. 
This derivatization removes the anomeric centre of the sugar in order to 
give only one signal for each sugar in gas chromatography. The main 
drawback is that different sugars can lead to the same alditol. For example, 
fructose can be equally convert to glucitole or mannitole because the 
reduction of the ketonic group is not stereo specific. 
The Partially Methylated Alditol Acetates (PMAA) is the best method 
and one of the only available for sugar linkage analysis. The procedure 
consists in a first permethylation step, that involves the addition of methyl 
groups (CH3) to all of the hydroxyl and N-acetyl groups. Methyl also 
esterifies the carboxy function on the sialic acid. The modified glycans will 
then undergo the alditol acetate procedure, as described above. In this way, 
it is possible to identify the linkage of the glycans by analysis of the 
fragmentation spectra, since the hydroxyl groups that were involved in the 
glycosidic bond are now acetylated and all the hydroxyl that were free are 
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now methylated. (Ruiz-Matute AI et al. 2011; Hellerqvist CG 1990).  
(Figure 12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Derivatization of sugar for linkage analysis. The glycan is 
permethylated before acid hydrolysis and then acetylated. (Essentials of 
glycobiology, Second Edtion Chapter 47, figure 3) 
 
The permethylation techniques that have been developed for PMAA 
analysis have been also successfully applied to MALDI-MS and ESI-MS 
analysis of glycans. Permethylation of glycans offers several advantages. 
For instance, by increasing glycan hydrophobicity, it allows also Liquid 
Chromatography–Mass Spectrometry (LC-MS) analysis. Moreover, since 
also the carboxy functional group of sialic acid is also methylated, losing 
the negative charge, both neutral and acidic glycans can be detected in 
positive ion mode using MALDI-TOF-MS. The protection of the hydroxyl 
group with a methyl group will also increase stability and the samples can 
be kept for months at room temperature. Methylation of the hydroxyl 
groups gives a better sensitivity and increase the hydrophobicity of the 
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sugars making easier to remove salts and polar contaminants with 
chromatographic methods. 
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1.3.2 Mass spectrometry analyses and 
ionization techniques 
 
The most commonly used instruments to study glycans in mass 
spectrometry, and in general biopolymers, are Matrix-Assisted Laser 
Desorption/Ionization Time-of-flight Mass Spectrometry (MALDI-TOF 
MS) and Electrospray Ionization- Mass Spectrometry (ESI-MS). 
In MALDI, as the name suggests, the ionization is assisted by a matrix 
that absorb the laser energy and help to ionize the molecule mixed together. 
In this way can be observed even analytes that are very difficult to ionize. 
MALDI has the advantage that data are obtained with minimal sample 
concentration and it is very tolerant with salts contamination. The main 
drawback is that there is a significant degree of fragmentation when 
negative glycan substituents, like sialic acid, sulfate, and phosphate groups 
are present (Zaia J 2010). For this reason, it is better to analyse 
permethylated glycans that are considerably more stable than their native 
counterparts avoiding the risk of fragmentation during the MALDI 
ionization. 
Another ionization source that can be used is Electrospray Ionization 
(ESI), in which a high voltage is applied to a liquid in a small capillary 
creating an aerosol. ESI has the advantage to be able to analyse native 
acidic glycans without glycans fragmentation and usually the signals are 
better resolved because the absence of matrix adduct peaks. On the other 
hand, the spectra are more complex due the different charge state and the 
sample must be free of salts. 
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1.3.3 MALDI TOF matrix choice 
  
The first step before proceeding with a MALDI analysis is the matrix 
choice. The sample has to be co-crystallized on a MALDI metal plate with a 
large excess of matrix in order to be analysed with this technique. Laser 
irradiation of the matrix induces electronic excitation of the matrix 
molecules. This cause desorption of the analytes and matrix ions from the 
surface of the crystal to be analysed and by the mass spectrometer in the 
positive or negative ion mode, in an appropriate m/z range. 
There are different matrices suitable for MALDI analysis and the choice 
will depend on the molecule to be analysed. For example, the most common 
matrix to analyse peptide is the alpha-cyano-4-hydroxycinnamic acid that 
give good results with peptides and small molecule in general, but is less 
indicated than sinapinic acid in the case of proteins. In particular, glycans 
are usually analysed with two different matrices: the 2,5-dihydroxybenzoic 
acid (DHB) and 3,4-diaminobenzophenone (DABP). Both can be used with 
good results, but some studies (Khoo K-H et al. 2010) suggest that DHB is 
in general better for detecting glycans in the positive ion mode, instead 
DABP gives the best sensitivity for detecting permethylated sulfated 
glycans in negative ion mode. 
 
1.3.4 MALDI TOF analysis of glycans 
 
The preparation of sample for MALDI require mixing of the sample with 
an acidic matrix and drying a microliter volume on a MALDI plate, to 
allow the formation of crystals. When hit by the pulsed laser beam, the 
matrix absorbs the energy of the UV light; the top surface of the dried drop 
heats and a small part is vaporized, carrying intact ionized glycans. 
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As already mentioned above, the mass spectrometer can be set in the 
positive or negative ions for analysis. In the case of permethylated glycan it 
is suggested to perform the analysis in positive ion mode, because the 
sialylated species are no more negatively charged. Even mono sulphated 
glycans give good results in positive mode. The ionized glycans are then 
accelerated by an electric field and the time that each ion need to reach the 
detector will depend on the mass-to-charge ratio.  The instrument then 
determines the mass-to-charge ratio via time measurement. The most 
commonly used detector to measure the time of flight is the electron 
multiplier, which consists in continuous or discontinuous dynodes series. 
When a charged particle hits the first dynode, it produces the emission of 
several electrons, which are then attracted to a second dynode and the 
process can continue on cascade amplifying the signal, in order to produce 
an electric current that can be read by the electronic system.   
The final spectra of the MALDI TOF analysis contains different peaks in 
a particular m/z range each of which correspond to a different glycan. 
Structures are assigned to each peak in the MALDI “fingerprinting”, which 
is based on the glycan composition (given by an m/z value) and the 
knowledge of the glycans biosynthetic pathways. Then it is possible to 
confirm the structure with MS/MS analysis. 
 
 
 
Figure 13. Diagram showing the steps of a MALDI TOF analysis 
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There are general rules to determine the molecular weight of a glycan, 
which are depicted in Figure 14. As shown in the figure, when calculating 
the molecular weight, it is important to consider the contribution of each 
monosaccharide and its substituents, as it is the case for methyl groups. 
Moreover, Figure 14 also shows that the method used for glycan release can 
have an important effect: for N-linked glycans, which are released by means 
of PNGase, the aldehyde group at reducing end is retained. On the contrary, 
for O-linked glycans the β-elimination procedure leads to the reduction of 
the aldehyde group of the first monosaccharide and the subsequent 
permethylation. This modification must be considered during mass spectra 
interpretation. 
 
Figure 14. The molecular weight of the permethylated glycans can be 
obtained by considering the sugars composition and the permethylated mass 
ends. A. N-Glycan released with PNGase F follow the general rule: total 
sum of Permethylated Residues Mass + 46 + Na+, where 46 represent the 
weight of the permethylated mass ends. B. For the O-glycans, reductive 
elimination leaves a free anomeric carbon and an additional site of 
permethylation on C5, so the resulting mass will be total sum of 
Permethylated Residues mass + 62 + Na+. (Morelle W et al. 2007) 
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A chart reporting the mass of the permethylated monosaccharides that are 
found in human glycoproteins and the corresponding symbols that are used 
to depict glycan structures is reported in Figure 15. 
 
Monosaccharide Symbol 
Permethylated 
Residue Mass 
(m.u.) 
Deoxyhexose 
 
Fucose (Fuc) 
 
174 
Hexose 
 
Galactose (Gal) 
 
Mannose (Man) 
 
204 
N-acetylhexosamine 
N- acetylglucosamine 
(GlcNAc) 
245 
Sialic acid 
 
N-acetylneuraminic acid 
(NeuAc) 
N-glycolylneuraminic acid 
(NeuGc) 
361 
 
 
391 
 
 
Figure 15. The symbols used to illustrate glycan structures and the 
molecular mass contribution of each monosaccharide to the final mass of a 
permethylated glycans. 
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1.3.5 MALDI TOF/TOF analysis 
 
In MALDI TOF/TOF ions are desorbed and ionized from the MALDI 
plate and then accelerated in the first TOF analyzer. Here, fragments 
continue to travel with the same velocity of the parent ion.  At the end of the 
first TOF, only the ions of the selected mass and the derived fragments can 
pass to the second TOF. In the second TOF, the ions are accelerated, but this 
time fragments and parent ion will be separated and their time of arrival on 
the detector will be different (Pusch W et al. 2003). 
This technique can be used to understand glycans composition starting 
from the m/z value of the parent ion and its fragments. For example, it is 
possible that different structures have the same m/z value, since mass gives 
no information about the sugar sequence or the type of linkage. Moreover, 
most sugars found in glycoproteins are isomers (GlcNAc- GalNAc) or 
epimers (Man-Gal). To overcome this problem, it is possible to use MS/MS 
fragmentation spectra to establish the structure of a glycan. Indeed, MS/MS 
is able to distinguish different glycans in most of the case, because it gives 
information about the fragmentation that can be different despite the same 
sugar monomer composition and the same mass. In this way, it is also 
possible to resolve different species that in MALDI-TOF analysis are 
represented by the same peak and to determine the relative abundance of 
each one. 
In detail, the analysis is based on the knowledge of the glycans 
biosynthetic pathway, which depends on the organism and tissue, and the 
mass of the sugar monomer. An example is shown in Figure 16. Both the 
indicated structures have a molecular weight of 2635.3. However, when the 
molecules are subjected to MS/MS, they produce different fragments, 
which have significantly different masses. Based on the fragments it is 
possible to assign unequivocally the glycan structure. 
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Figure 16. This image shows different glycans structure with the same 
molecular weight (2635.3 m.u.) but different fragments. (Drawn with 
Glycoworkbench) 
 
Figure 17 reports an example of a MALDI-TOF MS/MS spectra of a 
permethylated glycan. The specie with 2360.1 m/z has been subjected to 
further fragmentation. Analysis of the generated fragments is consistent 
with and validate the proposed structure of the parent specie. 
 
 
 
Figure 17. An example of MALDI TOF/TOF annotated spectra. 
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1.3.6 Glycoworkbench 
 
GlycoWorkbench (Ceroni, A. 2008) provides an easy to use suite that 
allows a simpler identification of glycans by knowing the m/z values of the 
parent molecules and/or the fragmentation spectra. The editor gives an easy 
way to draw glycans, where it is possible to build sugar by sugar the 
complete structure. To calculate the correct molecular weight there are 
several options that consider possible modifications in order; in particular, it 
can be selected if the glycans are permethylated, with a reducing end, a free 
end, with sodium charges and so on. 
A very good feature is the peak finder, which is able to find possible 
glycans that match with a particular m/z. However, it is necessary to have a 
very good knowledge of glycans possible structures to limit the number of 
hits. For example, if looking for N-glycans it will be good to search only for 
glycans with the GlcNAc2Man3 core. 
Another important tool is the fragmentation prediction, which can show a 
list of fragments for a given structure. This is helpful for tandem mass 
sequencing because, as evidenced by Figure 18, the software reports the 
m/z and the mass of each fragment, which can be compared with the data 
obtained from the MS/MS for a selected peak. 
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Figure 18. The working area of the Glycoworkbench suite: drawing, 
spectra trace, and fragment prediction. 
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1.4 Aim of the study 
 
Modification of glycan structures is now recognized as a hallmark of 
several pathologic conditions, from inflammation to cancer and 
degenerative diseases. Altered glycosylation has been identified in several 
neurodegenerative diseases of the CNS (Kizuka Y et al. 2017). However, 
little information is presently available about the role of glycosylation in 
PNS pathologies. 
Animal models represent an essential system to study the development 
and the physiopathology of the nervous system, due to the intrinsic 
difficulties for the use of samples of human origin (Martini R et al. 1997). 
For this reason, several transgenic and knock-out mice and rats or animals 
with spontaneous mutations have been established, mimicking hereditary 
human pathologies of PNS, such as CMT and related diseases. 
However, it remains difficult to work with mice as animal models of the 
neurodegenerative diseases since the extremely limited amount of myelin 
that can be recovered from peripheral nerves in respect of CNS. Therefore, 
miniaturizing the process will help to acquire important data on animal 
models of diseases and to cut the cost of the animal facility. 
The aim of this study will be focused on the optimisation of a method to 
perform a glycomic analysis, using MALDI-TOF mass spectrometry, from 
a very small amount of tissue from the peripheral nervous system of mice. 
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Materials and Methods 
 
Potter homogenization 
Ultracentrifugation sucrose gradient for myelin purification
Glycoproteins extraction
Cleavage of S-S bridges and protection of Cys 
Proteolytic digestion
N-glycans release
Permethylation of released N-glycans
Maldi TOF (Mass-fingerprinting)
Maldi TOF-TOF (Sequencing)
Hplc ESI MS for peptides 
analysis
SDS-PAGE and western 
blotBradford
 
 
 
 
Figure 19. Overall procedure for the preparation and analysis of glycans 
from biological samples. 
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2.1 Myelin purification from C57BL 
mice sciatic nerves. 
 
2.1.1 Myelin homogenization and 
ultracentrifugation 
 
C57b mice were maintained and used at the animal facility of CBA-San 
Martino Hospital, Genova, following the international rules for 
experimental animal welfare and experimentations were approved by the 
internal ethical committee. Sciatic nerves were obtained from WT control 
mice used for other experiments. Nerve were collected immediately after 
animal sacrifice and snap frozen in liquid nitrogen. They were then stored at 
-80°C until processed. 
Myelin can be enriched from homogenized sciatic nerves by sucrose 
gradient centrifugation, as the low-density membranes tend to accumulate 
in the interphase between 0.32 and 0.85 M sucrose. This method was 
initially proposed by Norton and colleagues (Norton WT. et al. 1973). 
Sciatic nerves from C57b mice (16 to 7 animals) were homogenized in 
buffer A (0,32 M sucrose, 10 μl of Protease Inhibitor Cocktails (PIC) 
[Sigma P8340-1ML], 2 mM EGTA) with Potter-Elveheim homogenizer. 
Different experiments proved that the best ratio to achieve a good 
purification is 1:20 between sample weight and solution. The centrifugation 
tube was initially filled with buffer B (0,85 M sucrose, 10 μl PIC, 2 mM 
EGTA) and the homogenate was then carefully layered on top of buffer B. 
The ratio of buffer A and buffer B must be 1:1. The tube was centrifuged 
with a TL-100 Beckmann® for 30 minutes at 4°C at 75,000 x g. The 
sucrose interphase was collected with a Pasteur pipette and placed into a 
clean tube. At this step, myelin membranes should be visible as a whitish 
cloud. It is possible that some contaminants can remain trapped in the 
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interphase layer, but nuclei and mitochondria are generally mostly found in 
the pellet of the gradient. To get rid of the remaining membrane 
contaminants, an osmotic shock in Milli-Q water was performed:  the tube 
containing the recovered interphase was filled with water and incubated on 
ice for 10 minutes.  The sample was then centrifuged for 15 minutes at 4°C 
at 75,000 x g. The pellet containing myelin was then resuspended again 
with 2 ml of Milli-Q water and centrifuged for 15 minutes at 4°C at 75,000 
x g. The washed pellet from the last step containing myelin can be 
preserved at -20°C dry or in a water solution for few days. 
 
2.1.2 SDS-PAGE and western blot 
 
The protein concentration in the purified myelin was estimated using the 
Bradford assay. To follow the purification steps, the different fractions 
obtained after centrifugation were analysed by a 10% acrylamide SDS-
PAGE, followed by Coomassie staining. A parallel SDS-PAGE was used for 
Western blot analysis. The separated proteins were transferred to a 
nitrocellulose membrane (Bio-Rad) by blotting overnight at 90 mA at 4°C 
in blot buffer (25 mM TRIS, 0.38 mM Glycine, 20% methanol, 0.1% SDS). 
Next, the membrane was blocked in 5% milk powder solution in PBS/ 0.1% 
Tween20 for 1 hour. The primary antibody anti-Myelin Protein Zero 
(ab31851, abcam) was used diluted 1:4000. After three washes with 
PBS/0.1% Tween to eliminate non-specific binding, the membrane was 
incubated with a secondary antibody (α-mouse conjugated with HRP, Santa 
Cruz Biotechnology). Detection was performed by a chemiluminescent 
method (ECL-GE Healthcare) using a ChemiDoc (Bio-Rad). 
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2.2 Glycans purification from myelin 
 
2.2.1 Glycoprotein extraction 
 
For glycoprotein extraction, the Folch chloroform-methanol method was 
used. Before starting with the sonication step, the sonicator probe was 
extensively washed with methanol and chloroform solution to avoid 
contamination. The myelin enriched sample was transferred to a clean 15 
ml falcon tube, and the final sample volume was brought to 2 ml with Milli-
Q water so that would be easier the to facilitate the sonication. The sample 
was sonicated in continuous mode at 40 Amps for 10 seconds followed by 
2-3 minutes on ice and this process was repeated for 5 times. 
Under fume hood, 2.67 volumes of methanol were added to the 
homogenate and mixed vigorously; then, 1.33 volumes of chloroform were 
added and the homogenate was vortexed. The sample was centrifuged for 
10 min at 3000 rpm (in a tabletop centrifuge) to pellet proteins. However, 
the proteins stayed in the interphase instead of precipitate, so was necessary 
to remove the top aqueous layer, containing salts and nucleic acids, and add 
methanol to complete the precipitation (Wessel, D et al. 1984). 
Specifically, the upper phase was carefully removed without disturbing 
the interphase and another 1 ml of methanol was added. The sample was 
centrifuged again for 10 min at 3000 rpm. After this second centrifugation, 
the proteins precipitated in the pellet, which was collected and dried under 
nitrogen to remove excess of chloroform/methanol. 
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2.2.2 Reduction, carboxymethylation and 
trypsin digestion 
 
The pellet containing the precipitated proteins sample was resuspended 
in 0.5 ml of a DTT solution (DTT 2 mg/ml in degassed Tris/HCl 0.6 M pH 
8.5), incubated for 60 min at 37°C and then briefly centrifuged to pull down 
the condensation. Then, 0.5 ml of iodoacetic acid (IAA) solution (12 
mg/ml) were added and the sample was incubated in the dark at room 
temperature for 90 min. 
The glycoproteins sample was transferred to a high-quality dialysis tube 
(Slide-A-Lyzer™ cut-off 10k or SnakeSkin™ Dialysis Tubing cut-off 7k; 
Thermofisher) and sealed. The carboxymethylation reaction was terminated 
with by a 48 hours dialysis for 48 hours in AMBIC buffer (50 mM 
ammonium hydrogen carbonate pH 8.4), changing the buffer regularly 4-5 
times/day. 
The dialysed sample was transferred into a 15 ml Falcon tube with a 
Pasteur pipette and, after the addition of 20 μg of trypsin (porcine T0303, 
Sigma), it was incubated for 24 h at 37°C. It was not necessary to stop the 
reaction since an unprotected trypsin, which undergoes through autolysis, 
was used. 
Three drops of 5% acetic acid were added to the glycopeptides solution 
to lower the pH for the further Sep-Pak® purification. An Oasis HLB Plus® 
cartridge was attached to a 5-ml glass syringe and conditioned with the 
sequential addition of 5 ml of methanol, 5% acetic acid, 100% propanol and 
15 ml of 5% acetic acid. 
The sample was loaded using a plastic syringe, then the cartridge was 
washed with 5 ml of 5% acetic acid. Sequential elutions were done with 4 
ml of 20 % propanol, 40% propanol, and 100% propanol. The three 
fractions were pooled together in a Corning glass tube and the volume was 
reduced with using a SpeedVac. All the collected fractions were combined 
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in the 20% propanol tube. The sample was finally lyophilised in a freeze-
dryer. 
2.2.3 N-glycans release 
 
The lyophilised sample was resuspended in 250 μl of AMBIC buffer 
containing 5 U of N-glycosidase F and incubated at 37°C for 24 h. A second 
aliquot of the glycosidase was added after 8 hours. After the incubation, the 
sample was centrifuged. 
The released N-linked glycans were separated from the mixture 
containing the residual peptides, using the same Sep-Pak® C18 method 
used after trypsin digestion. N-glycans were eluted from the cartridge using 
5 ml of 5% acetic acid. The volume was reduced with SpeedVac and the 
sample was finally lyophilised in a freeze-dryer. The peptides and the O-
linked glycopeptides were eluted using the three solutions with increasing 
propanol concentration, as described above. The eluted propanol fractions 
were pooled and, after volume reduction by Speed-vac, they were subjected 
to lyophilisation. 
 
2.2.4 Dowex preparation and O-glycans 
release 
 
To prepare 100 g of Dowex beads, 100 g of 50W X8, 50-100 mesh 
Dowex beads were added to 100 ml of 4 M HCl and left to decant. This 
wash was repeated twice more. Then beads were washed 15 times with 
Milli-Q water until the pH was stable at 6.5. Moreover, the beads were 
finally washed with 150 ml of 5% acetic acid and were left immersed in this 
solution. The beads can be stored in this solution for years. 
A reducing solution (400 μl of 1,5 M KBH4, 0,1 M KOH in Milli-Q 
water) was added in a Teflon-lined screw-capped tube (Corning) to the 
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lyophilised propanol fraction from the Sep-Pak® purification. The mixture 
was incubated for 14-16 hours at 45°C. The reaction was terminated by 
adding 5 drops of acetic acid until the fizzing stops. A desalting column was 
assembled using a Pasteur pipette fitted with a bottom filter of glass wool 
and about 1 ml of Dowex beads upon. A silicone tube was placed at the 
tapered end to control the flow. 
The Dowex column was conditioned with 15 ml of 5% acetic acid. Then 
the sample was loaded and the flow through was collected; the beads were 
further washed with 5 ml of 5% acetic acid and this second elution step was 
pooled with the preceding one.  The volume was reduced with SpeedVac 
and the sample was then lyophilised in a freeze-dryer. To remove better the 
excess of borates, the sample was resuspended 4 times with 0.5 ml in 
methanol-acetic acid 9:1 and dried under a nitrogen stream at room 
temperature. To eliminate residual water, the sample was finally lyophilised 
again in a freeze-dryer. 
 
2.2.5 HPLC ESI MS for peptides analysis 
 
The analysis was done by the Biopolymer Mass Spectrometry unit, 
Imperial College London, and it was performed on a small volume of the 
O-glycopeptides fraction. The peptides were separated on a Pepmap C18 
nanocapillary column (15 cm length, 75 mm internal diameter) fitted to a 
nano-HPLC system (LC Packings) connected to an ABI QSTAR Pulsar 
Hybrid LC/MS/MS system (Applied Biosystems/MDS Sciex). A gradient 
from 0.05 % (v/v) formic acid in 95.5 % (v/v) water/acetonitrile to 0.05 % 
(v/v) formic acid in 95.5 % (v/v) acetonitrile/water was employed. Data 
were analysed using the Analyst QS Software. 
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2.3 Glycans permethylation and 
purification 
 
2.3.1 Glycans permethylation 
 
Before starting this procedure (North S.J et al. 2010), the sample has to 
be dried. Anhydrous DMSO (3 ml) was added in a dry glass mortar to 5 
pellets of NaOH; the pellets were crushed with a glass pestle until the 
formation of a slurry. This was done quickly to avoid excessive absorption 
of moisture. This amount of slurry is required for 2 samples, the N-linked 
and the O-linked released glycans; 1 ml of the slurry was transferred with a 
Pasteur pipette to the glycan sample and immediately 0,7 ml of methyl 
iodide were added using a Gilson pipetting device equipped with a plastic 
tip. The samples were vortexed and then shaken for 2h at 4°C (Khoo K-H et 
al. 2010). The reaction was quenched by slow additions of cold 5% acetic 
acid with constant shaking to lessen the effects of the highly exothermic 
reaction. The pH was checked with a pH indicator to ensure that the sample 
pH is neutral or slightly acidic. 
At this point 1.5 ml of chloroform were added and the sample was mixed 
thoroughly and then settled to allow the formation of two layers. The upper 
aqueous layer, which contains the sulfated permethylated glycans, was 
removed and transferred into another clean tube ready for Sep-Pak 
purification. 
The organic phase, containing the neutral glycans, was washed 4 times 
with 5 ml of ultra-pure water, using a table centrifuge; the sample was then 
dried under a gentle stream of nitrogen and kept dried at -80°C until the 
further purification step. 
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2.3.2 Purification of neutral permethylated 
samples by Sep-Pak® C18   
 
The Sep-Pak® cartridge was conditioned by sequential washes with 
methanol (5 ml), ultra-pure water (5 ml), acetonitrile (5 ml) and ultra-pure 
water (15 ml). The sample obtained from the organic phase of the step 
above, containing the neutral glycans, was dissolved in first 100 μl of 
methanol, then 100 μl of water were added.  The resuspended sample was 
loaded with a Pasteur pipette onto the Sep-Pak® Cartridge and washed 
stepwise with 5 ml of Milli-Q water and 3 ml of 15% acetonitrile. 
The permethylated glycans were eluted with 3 ml of 35%, 50% and 75% 
acetonitrile/water solutions and all fractions were collected in different 
glass tubes. The volume was reduced by SpeedVac to about 1 ml or less 
before lyophilising with a freeze dryer. The purified permethylated glycans 
are stable and can be conserved at room temperature for months. 
 
2.3.3 Purification of sulfated permethylated 
samples by Sep-Pak® C18 
 
The Sep-Pak® cartridge was conditioned by sequential washes with 
methanol (5 ml), ultra-pure water (5 ml), acetonitrile (5 ml) and ultra-pure 
water (3x5 ml), as described above in the previous paragraph. 
The aqueous fraction obtained after permethylation was loaded, with a 
Pasteur pipette, onto a plastic syringe (used only for loading onto the Sep-
Pak®) and washed stepwise with 15 ml of Ultra-pure water and 3 ml of 
10% acetonitrile. The permethylated glycans were eluted with 3 ml each of 
25% and 50% acetonitrile/water solution and the two fractions were 
collected in different glass tubes. 
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The volume was reduced by SpeedVac® to about 1 ml or less before 
lyophilising with a freeze dryer. The sample can be conserved at room 
temperature for months and it is quite stable; however, the sulfate groups 
may be lost. 
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2.4 Sample preparation and MALDI 
Analysis 
 
2.4.1 Sample preparation 
 
The lyophilised sample was dissolved in 10 μl of methanol and vortexed. 
One μl was combined with 1 μl of DABP (3,4-diamino-benzophenone) 
matrix solution (10 mg/ml) and spotted on a MALDI plate. The procedure 
was repeated for all the lyophilised Sep-Pak® acetonitrile fractions. After 
spotting all the samples the MALDI plate was put under vacuum and dried. 
 
2.4.2 Preparation of calibrant solution for 
MALDI analysis 
 
For the MS analysis the calibration was done using a peptide calibrant 
(100 mg/ml of peptide/protein mix Calmix-leucine enkephalin, bradykinin 
(fragment-8), angiotensin I, ACTH fragment 1–17, ACTH fragment 18–39, 
ACTH fragment 7–38, ACTH fragment 1–39 and insulin (bovine pancreas) 
in 0,1% TFA water). 
For the MS/MS analysis a different peptide calibration solution was used 
consisting in: 1 pmol/ml solution of [Glu1]-fibrinopeptide B in 1:3 (v/v) 
acetonitrile/5% acetic acid (v/v). 
The matrix used for peptides calibrants was composed by 10 mg/ml 
alpha-cyano-4-hydroxycinnamic acid in 50% acetonitrile in 0.1% (v/v) TFA 
in water) 
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2.4.3 MALDI TOF Mass-fingerprinting 
 
MS data were acquired using a 4800 MALDI-TOF/TOF (Applied 
Biosystems) mass spectrometer. For the calibration, as described above, a 
laser intensity of 2200 was used and a 50 shots/spectrum were recorded. 
The calibration was done after accumulation of three spectra. The analysis 
was done in positive ion mode for the neutral permethylated N-glycans and 
in negative/positive ion mode for the sulfated N-glycans. 
For the MALDI-TOF fingerprinting were used the following parameters: 
-Laser intensity: 3500, Positive reflectron, with delayed extraction 
-Mass range: m/z 500–5000, 
-Low mass gate: m/z 500, 
-Accelerating volts: 20 kV, 
-Grid: 60–78%, 
-Delay time: 220–280 ns. 
 
2.4.4 MALDI TOF-TOF sequencing 
 
MS/MS data were acquired using a 4800 MALDI-TOF/TOF (Applied 
Biosystems) mass spectrometer and the collision gas used was Argon. The 
system was calibrated with the peptides calibrant solution and then was 
ready to be used. 
For the MALDI-TOF TOF sequencing were used the following 
parameters: 
-mode: Positive reflectron, with metastable ion suppression 
-laser intensity: 5000–6000 
-shots: 1000 shots/spectrum, accumulate 10 spectra, 
-mass range: m/z 50–5000, 
-accelerating volts: 20 kV, 
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-Source-collision 
-cell potential difference: 1 kV, 
-CID: On, CID gas type: Inlet 1—Medium weight, Collision gas: Argon 
    -Collision gas pressure: 10, 4 mbar. 
 
2.4.5 Data Analysis 
 
MALDI Data were analysed using Data Explorer 4.9 Software (Applied 
Biosystems). This software is able to read the raw format and show the 
mass spectrometer data in an easy graphic interface. It is possible to set a 
cut off for abundance peak recognition, smooth graphic and select m/z 
range to analyse even small peaks. Majors peaks were then annotated 
manually (GlycoWorkBench software) with their respective structure, 
which was then confirmed by MS/MS fragmentation analysis. 
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Results 
3.1 Optimization of myelin enrichment 
method 
 
This myelin enrichment protocol is based on the Norton WT et al. 1973. 
The first experiments were devoted to the optimization of myelin 
enrichment from very small amounts of starting material, i.e the mouse 
sciatic nerves. The Potter-Elvehjem homogenisation method, despite it 
requires a long time and effort, was the best method tried to homogenise the 
samples. During this procedure, an insoluble aggregate could form, 
probably composed of connective tissue, which could not be homogenised 
even by vortexing. To avoid this aggregate formation, a second procedure 
was tried: sciatic nerves were homogenised with an Eppendorf pestle after a 
snap freeze step. This last method was faster and easier, but the aggregate 
was even bigger, so it was necessary a further step of Potter-Elvehjem 
homogenisation to recover the sample. 
The final protocol was set up using a volume of less 1 ml with a minimal 
tissue amount. The lowest amount of material that could be processed with 
this protocol was derived from sciatic nerves of seven 28-days old mice. 
Yield of material was maximized by adding a second 500 μl wash of the 
glass and Teflon surfaces.  A TL100 Beckmann® Centrifuge was then used 
for fractionation: even if it has a fixed angle rotor, and not a swinging 
bucket as suggested in the published protocols, it was possible to obtain a 
clear separation of the interphase enriched in myelin membranes. When the 
starting nerve material is very low, the interphase containing myelin is still 
well visible in a 3 ml or smaller centrifugation tube, while it was difficult to 
notice in larger ones. The following steps, osmotic shock and further 
centrifugation, allowed the quantitative recovery of the myelin-enriched 
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fraction in the pellet. The yield of protein was quite consistent among the 
different purifications. This procedure was also applied to very small 
amounts of rat brain (100 mg), giving the same results (not shown). 
For glycan analysis, the second gradient purification and osmotic shock 
suggested by some published protocols were omitted, because the results 
obtained in ESI/MS (see below Table 3) indicated a very low contamination 
by proteins from other cell types already after the first purification step. On 
the other hand, a second gradient purification caused a further loss in 
sample recovery. 
The protein concentration in the myelin enriched sample was estimated 
by Bradford Assay; about ≈ 500 μg of myelin proteins were recovered from 
≈ 100 mg of tissue. This yield from the gradient purification ensure a 
sufficient amount of material, since the protocol used for glycan 
purification is highly optimized and the MALDI-TOF analyser has a high 
sensitivity. 
SDS-PAGE and Western blot have shown that, during the gradient 
purification, myelin proteins were highly enriched. Figure 20 shows that the 
washed interphase (PI) contains only few proteins, compared to the upper 
and lower phases of the gradient; the most abundant band has a molecular 
weight consistent with MPZ (27 kDa). This band was further confirmed to 
be MPZ by Western blot analysis with an α-MPZ specific antibody. All the 
high molecular weight proteins were not found in the washed interphase, 
indicating that purification was successful, as also confirmed by 
comparison of the SDS-PAGE pattern with the published ones (see Section 
1.1.1 Figure 4). The purified interphase (PI) was then used for 
glycoproteins extraction. 
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Figure 20. SDS-PAGE and Western blot (αMPZ) analysis of fractions 
obtained during myelin enrichment by sucrose gradient purification. St. 
molecular weight standards, U upper phase, L lower phase, P pellet, W1 
Wash 1, W2 Wash 2, PI purified interphase. 
 
ESI-MS proteomic analysis was used to confirm the identity of the 
purified proteins in the purified interphase enriched in myelin membranes. 
As shown in Table 3, besides porcine trypsin that was used for digestion, 
the most abundant peptides identified by ESI-MS were tubulin, MPZ, 
periaxin and MBP, all proteins typically found in compact myelin. No other 
contaminants were found at significant concentration.  Among proteins that 
have high score hits, it is interesting to note that MPZ is the only 
glycosylated one. This suggests that the glycans are derived mainly from 
MPZ and this can be valuable to study glycans in MPZ associated 
pathologies. In the Supplemental Table 1 (ST1), all the peptides derived 
from MPZ that were found in the ESI/MS analysis are shown in detail. 
Moreover, all the peptide hits obtained by ESI/MS analysis are reported in 
Supplemental Table 2 (ST2). 
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Table 3. Table showing the best hits of the ESI-MS Analysis. The full 
table can be found in the supplemental table 2 (ST2) 
 
3.2 Optimization of glycans 
purification 
 
Once the myelin has been purified, the next step is the optimization of 
the procedure from myelin-enriched sample to purified glycans. 
The first passage is the glycoprotein extraction using the Folch Method, 
which consist in the precipitation of proteins with the concomitant removal 
of the lipid contaminants using methanol and chloroform. This method can 
be difficult operating with a small amount of sample; in this case, after 
centrifugation, proteins will tend to stay in the interphase instead of forming 
a precipitate. The best solution to avoid this problem was found in literature 
(Wessel, D et al. 1984) and consists in removing all the upper-phase above 
the sample, adding methanol and centrifuging again. In this way, proteins 
will precipitate at the bottom of the tube and will be ready for the next step 
of reduction and carboxymethylation. 
The dialysis step to stop the reduction/carboxymethylation reaction was 
also improved by using Slide-A-Lyzer™ mini device. The original protocol 
suggested using SnakeSkin™, which is cheaper, but it can be difficult to 
handle and it has a large surface where proteins can bind and be lost.  Slide-
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A-Lyzer™ mini device offers the advantage of a quick buffer change and 
the possibility to keep the volume very small. In our conditions, this latter 
device proved to be significantly better over the SnakeSkin™ and no 
drawbacks were evidenced using Slide-A-Lyzer TM. 
The main advantage to keep the volume small is that the sample can be 
dialysed in AMBIC, then directly transferred to a clean tube where trypsin 
can be directly added to start the proteolytic reaction. This modification 
avoids using SpeedVac or lyophilisation to reduce the volume after dialysis. 
Another important consideration to maximise glycan recovery is to 
prefer a Freeze-drier to a SpeedVac to lyophilise the sample after the 
glycans release and purification step. If a SpeedVac is used, it will be very 
difficult to resuspend a completely dry sample without water and some 
glycans will be lost. 
  The entire procedure was repeated several times. Using 14 sciatic 
nerves from 28-days old mice, the main glycans peaks are still visible (data 
not shown). However, when very low concentration of proteins is handled, 
it is possible that the minimal contaminants in the sample, even at 
extremely low concentration, will prevail during the analysis, masking 
relevant signals and making difficult data interpretation. The most common 
contaminants that are very difficult to avoid are polyehyleneglycole and 
keratin. Therefore, extreme care must be used to avoid all possible 
contaminations, since the procedure is very repeatable and sensitive and 
contamination can represent the only one limiting factor. 
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3.3 Myelin glycoprofile of mice sciatic 
nerves 
 
Figure 21. MALDI-TOF-MS profiles of permethylated N-glycans (50% 
Actonitrile fraction) derived from C57BL wild-type murine glycoproteins 
of myelin. All molecular ions are [M + Na]+.  The two panels cover 
sequential m/z ranges. Putative structures were obtained with MS-MS 
analysis and annotated according to the Consortium for Functional 
Glycomics (http://www.functionalglycomics.org) guidelines. 
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The purified glycans obtained from the different fractions after the last 
cartridge purification were then subjected to MALDI-TOF analysis. 
MALDI-MS analysis was used to determine the m/z of the different 
species. Based on the expected molecular weight, a possible glycan 
structure was proposed using the Glycoworkbench software. At this point, 
the putative structures were confirmed by MS/MS analysis, by evaluating 
the m/z generation of fragments from the parent molecule. 
For neutral glycans, the fractions eluted from the Sep-Pack cartridge by 
35% and 50% acetonitrile elution were both analysed. The MALDI-MS 
profiles found in both fractions were comparable, the only difference was 
that the 50 % shown a better abundance, in particular of glycan species at 
higher molecular mass. 
Spectra of the 50% acetonitrile fraction are reported in Figure 21 and 
indicated the presence of neutral and sialylated N-linked glycans, mostly 
showing core fucosylated biantennary hybrid and complex structures. All 
the identified glycans are also summarized in Supplemental Table 3 (ST3). 
Both forms of sialic acid, the N-acetylneuraminic acid (Neu5Ac) and the N-
glycolylneuraminic acid (Neu5Gc) are found, in agreement with the 
presence of both sialic acid forms in mammals, with the exclusion of 
humans (Varki A. 2010). The α-Gal epitope, typical of mammals excluding 
humans, consisting of two terminal galactose residues is also evidenced 
(Larsen RD 1990). Conversely, the HNK-1 epitope, which has been 
reported to be present in mouse PNS myelin (Löw K. et al. 1994), was not 
detected. 
The polar permethylated glycans, containing the sulphated species, were 
eluted from the Sep-Pack cartridge using 25% and 50% acetonitrile. 
MALDI—TOF analysis was performed using both negative and positive 
mode. In negative ion mode, the spectra show only sulfated glycans, but 
with a low abundance. In positive ion mode, the analysis is more sensitive 
and it is possible to find also some neutral permethylated glycans. 
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Results of the 25 % fraction are reported in Figure 22 for negative mode 
and in Figure 23 for the positive mode. Both analyses provide similar 
results and reveal the presence of a high amount of mono-sulfated 
structures, which are indeed abundant in PNS myelin among mammals 
(Sedzik J et al. 2015).  All the identified polar glycans are also summarized 
in Supplemental Table 4-5 (ST4, ST5). 
 
Figure 22. MALDI-TOF-MS profiles of permethylated sulfated N-
glycans (25% acetonitrile fraction) derived from C57BL wild-type murine 
glycoproteins of myelin. All molecular ions are [M-H]-. 
 
Few low abundant species are found in the positive mode, which are not 
detected in the negative mode. It is interesting to note the presence also of a 
non-sulfated specie at 2399.1 m/z. This is because permethylated glycans 
can be found in the aqueous fraction if they have an incomplete 
permethylation. This happens because terminal sialic acid may form a salt 
bond with a Na+, covering a site of permethylation on the sugar, so the 
glycans remain polar and stay in the aqueous phase. This happens when the 
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permethylation is done at 4°C; as consequence, in order to have a better 
evaluation of the abundance of sialylated sugar, it is always better to 
analyse both the chloroform and the aqueous fractions. Moreover, it is 
important to note that in these cases the glycans have a molecular weight 8 
m.u. higher compared to the expected one, due to the presence of a sodium 
ion on the sialic acid (23 m.u.) instead of the methyl group (15 m.u) that 
was not inserted. In the Supplemental Figure 1 (SF1), there is an example of 
MALDI-MS/MS analysis, in which only the fragments with a sialic acid 
have a molecular weight 8 m.u. higher. 
 
 
 
Figure 23. MALDI-TOF-MS profiles of permethylated sulfated N-
glycans (25% acetonitrile fraction) derived from C57BL wild-type murine 
glycoproteins of myelin. Molecular ions completely permethylated are [M + 
(n+1)Na-nH]+ where n is the number of sulfated group.  The non-sulfated 
sialyl N-glycans have an incomplete permethylation on the terminal sialic 
acid and their resultant molecular ions are [M + 2Na - CH3]+ 
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It is difficult to assign unequivocally the position of the sulfate group 
using MALDI-MS analysis; in particular, it was not possible to establish if 
the sulfate group was on the antennary galactose or N-acetylglucosamine, 
but this information need to be obtained using other methods. This 
represents a limitation of the MALDI-MS analysis done. 
No other fractions obtained after cartridge purification of both the 
organic and aqueous phases revealed any glycans, as expected. 
The samples obtained after β-elimination, Dowex purification and 
permethylation were also analysed for O-linked glycan presence. However, 
no significant amounts were found, at least for the amount of starting 
material used in our experimental conditions. 
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Discussion 
 
Glycosylation is one of the most abundant form of post-translational 
modification of proteins. Many studies indicate that modifications of the 
glycosylation patterns either represent the basis for many diseases or can be 
signs underlying pathological conditions. However, glycosylation is often 
not considered enough, when studying pathogenetic mechanisms and the 
main reason is probably related to the difficulties of studying glycan 
structures. 
One first difficulty is related to the macro- and micro-heterogeneity of 
glycans (Stanley P et al. 2009). Each molecule of the same protein produced 
in a single cell can harbour different glycan structures at the same 
glycosylation site. At the same time, a single specific protein can show 
different glycosylation profiles when produced in different cell types or 
tissues or in different moments during development or in pathological 
conditions, such as neoplastic transformation. Indeed, aberrant 
glycosylation is considered one of the hallmark during tumour development 
(Munkley J et al. 2016). 
A second problem in studying glycans is because the final structures 
cannot be predicted simply by analysing expression of the relevant enzymes 
involved in the biosynthetic process. Glycoconjugate biosynthesis is 
influenced by several factors: i) activity of the metabolic pathways that 
provide the nucleotide-sugar substrates and their availability either in the 
cytosol and in the ER/Golgi lumen, which is conditioned by activity the 
specific transporters; ii) expression of the different glycosyltransferases, 
which add the monosaccharide units to the nascent oligosaccharide chain, 
or the glycosydases, which remodel the glycans; iii) localization of the 
enzymes in the secretory pathway and functionality and trafficking of the 
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Golgi cisternae and vesicles. Any modification in each of this factor can 
have profound effects on the final glycan composition (Varki A et al. 2009). 
A third problem is methodological and it is due to the difficulties to 
analyse carbohydrates, in particular in very small amounts. In a complex 
glycoconjugate each monosaccharide can be bound to another 
monosaccaride in four different C positions, with either α or β configuration 
of the linkage. In the past, very large amounts of starting material were 
required to determine the structure of complex carbohydrates, in particular 
to allow purification of glycans from other macromolecules (nucleic acid, 
lipids and proteins), in order to analyse them by chemical methods. Even 
today, linkage analysis can be done only using GC-MS of PMAA (partially 
methylated alditol acetates) or, to completely resolve the structure, by NMR 
(Mulloy B et al. 2009). However, both methods require large amounts of 
pure glycan species. Alternatives have been developed, for instance using 
HPLC after derivatization of the released glycans using fluorescent probes. 
These latter techniques proved to be useful to separate the different 
oligosaccharide structures, but they are time consuming and require the 
availability of standard glycans; in any case, large amounts of starting 
sample material are needed. Another method relies on the use of exo- and 
endo-glycosydases to specifically remove monosaccharide residues (i.e. 
sialidases or galactosidases) or complete glycan structures (i.e. PNGase, or 
endoH glycosidase) (Mulloy B et al. 2009). 
For the reasons stated above, the glycomic analyses are more 
complicated if compared to transcriptomic and proteomic analyses and 
despite the increasingly and widely recognized role of glycans in cell and 
tissue physiopathology, the number of studies is still limited. 
Most of drawbacks of glycan analysis have been partially solved by the 
introduction of mass spectrometry technique in glycan studies, both ESI-
MS and MALDI-TOF (Han L et al. 2013). Both techniques present 
advantages and disadvantages, but they can provide the glycoprofiles of the 
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cell or tissue under analysis, allowing easy comparison between different 
situations, i.e. health vs. disease or early vs. late developmental stages. Due 
to the high sensitivity of mass spectrometry, the amount of starting material 
required is usually lower compared to other methods. However, even if 
mass spectrometry is very precise to determine the composition of each 
glycan specie, a major drawback is that it is not possible to analyse the type 
of linkages (i.e. α or β and the C atom involved, if 1,2, 1,3, 1,4 or 1,6 
bonds), thus impeding the conclusive identification of isomeric forms. 
A second problem derives from the high sensitivity of the MS methods, 
in particular of MALDI-TOF, which makes the possible contamination from 
exogenous molecules a major problem. Since the sample needs to be 
extensively handled and many steps are required before MS analysis, it is 
possible to accumulate contaminants during the glycan purification and 
derivatization procedures. In particular, polyethylenglycole (PEG) and 
keratin represent the most frequently encountered challenge. PEG is usually 
contained in soaps and detergents and it can easily contaminate the sample. 
Keratin can be released by the skin during sample manipulation. To avoid 
contamination, it is better to work on a dedicated workbench in a cleaned 
room and with all the solutions prepared fresh daily. Another important 
consideration is to work with nitrile gloves, because latex may contain 
traces of natural rubber proteins. 
In the last few years, MALDI-MS and MS/MS technique has quickly 
become a standard in glycomic analysis. Several databases for glycan 
profiles from human and mouse tissues are already available (Lisacek F et 
al. 2017). Glycoprofiles of mouse tissues have been obtained for normal 
mice and after knock-out of specific enzymes involved in glycan formation 
(North SJ et al. 2010). These results allowed correlating glycan structures 
with the phenotypic manifestations of the genetic ablation. Moreover, 
studies were also performed on patients affected by CDG diseases, further 
expanding our knowledge on glycan function (Yoshinao et al. 2006). 
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In spite of the increasing amount of glycoprofiles for tissues of animal 
experimental models, in particular mouse and rat, little information are 
currently available for glycans derived for mouse and rat PNS myelin. 
Previous data relied on results obtained using antibodies and enzymatic 
treatments (Sato Y 1999). 
Very recently, the profile of mouse PNS myelin was obtained by 
bidimensional HPLC analysis (Yoshimura et al. 2017.). However, in this 
case, large amounts of myelin sample are needed. This can represent a 
limitation when working with very young animals, for instance to identify 
glycoconjugate changes during nerve development, or when studying 
models for demyelinating diseases, such as CMT knock-in mice. 
The need to have a reliable method to obtain glycoprofiles of PNS 
myelin using very low amounts of starting material prompted us to start this 
study, aimed to set up a protocol to use MALDI-MS analysis. To this 
purpose, the published protocols already set up for other types of mouse 
tissue were modified, in order to be applied to myelin sample. The modified 
protocol that was set up in this study allowed to obtain reliable results and 
proved that it is possible to use very low amounts of starting material. 
However, it also evidenced the problems raised by exogenous 
contamination when using such low amounts of material and the absolute 
need to prevent it by working in highly controlled conditions. 
The advantage of this procedure over the chromatographic method used 
by Yoshimura et al. is that, once the method is set, it is very fast and a 
complete analysis can be achieved in only two weeks treating up to 5 
samples or more in parallel. The only step that requires a lot of time is to 
resolve the first glycoprofile by MS/MS analysis. Once the glycoprofile is 
obtained it can be used as reference to the fragmentation spectra obtained 
by subsequent analyses, thus avoiding the need to interpret each peak again. 
Thus, this modified protocol will represent a valuable to analyse the 
glycan profile in mouse and rat models of human neurodegenerative or 
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other types of PNS diseases. Many CMT mouse models have been 
established (Bouhy et al. 2013), mimicking the mutations responsible for 
human diseases. This optimised protocol opens the way for difficult 
analysis, as in the case of these CMT mice models, in which the myelin is 
compromised and the quantity that can be recovered from the animal is low. 
Few models for CMT1B and CMT1A diseases have been already 
identified and are made available by our collaborators at San Raffaele 
Hospital in Milano, to analyse changes of myelin glycosylation during the 
course of the experimental diseases.  For instance, P0S63del mimics one of 
the most common mutations that affect MPZ in CMT1B patients (Blanquet-
Grossard, F et al. 1995). PMP22Tr-J also recapitulates the findings in 
patients affected by CMT1A (Henry EW et al. 1983).  In both conditions, 
the presence of the mutated or over expressed proteins induces ER stress 
and UPR (Brennan KM et al. 2015). It has been shown that ER-stress can 
also affect glycosylation patterns, thus it will be interesting to analyse the 
effect of these mutations on glycan expression. Another group of gain-of-
function mutations recently identified in MPZ has a consequence the 
insertion of new glycosylation sites, such as the P0D61N mutant, thus 
increasing the number of sugar chains on the protein (Prada V et al. 2012).  
A mouse model for this mutation is currently under development by Prof. 
Grandis at the DINOGMI, University of Genova and Prof. D’Antonio at 
San Raffaele Hospital. 
Other experimental models that would be worth to analyze are the mouse 
knock-out models for CDG, which mimic the mutations found in patients. 
Correlation between the histopathological finding in PNS nerves and 
glycans composition would provide useful information about the role of 
specific structures (i.e hybrid N-linked glycans) in myelin function. 
The optimized protocol can be also applied to rat myelin. Rat models can 
also used to study diabetic neuropathy or nerve regeneration after nerve 
crushing or resection and to follow glycosylation change during foetal and 
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neonatal nerve myelinization or during aging. The small amount of tissue 
required also open the possibility to apply this technique also to the small 
human sural nerve biopsies, to analyze glycosylation changes during 
pathologies, which have been not performed yet, for ethical reasons. 
Besides, MALDI ionization allows the use of a very low amount of 
sample. In this study it was possible to obtain good results using only 1 μl 
of the sample resuspended in 10 μl methanol, so it is possible to dry the 
remaining methanol under a gentle nitrogen stream and to save the 
permethylated sample for months, for instance to compare different 
pathogenic models in the same MALDI analysis. 
The glycoprofile obtained in this study is in agreement with the very 
recent data obtained using bidimensional DEAE-HPLC analysis 
(Yoshimura et al. 2017). Most of the N-linked glycans are biantennary 
hybrid type, showing different degree of sulfatation. The HNK-1 epitope is 
not present, in contrast with previous findings, which indicated its presence 
on the motor fibers only (Löw K. et al. 1994), while core fucosylation is 
common. The presence of large amounts of hybrid N-linked glycans is 
puzzling, since this type of structure is uncommon on mature structures 
exposed on cell surface. Indeed, hybrid N-linked glycans are formed as 
biosynthetic intermediates in the ER/Golgi and they are mostly converted to 
complex ones. Terminal α3 and α6 mannose residues are not normally 
found on mature glycoproteins in vertebrates. Knock-out mice for 
mannosidase II, which allows the conversion of the hybrid structures to the 
complex ones by removing the α3 and α6 mannose residues, display large 
amounts of hybrid glycans on cell surfaces. These mice develop severe 
autoimmune responses resembling systemic lupus erythematosus (Green et 
al. 2007, Chui D et al. 2001). This finding has been related to the 
recognition of exposed mannose residue by the mannose binding lectins of 
the innate immune response, thus promoting complement activation and 
deposition (Ohta M et al. 1994). It is possible that the presence of hybrid 
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structures has some role in the compaction of the myelin sheaths and further 
studies are needed to solve this issue. Moreover, myelin damage caused by 
CMT mutations could cause exposure of these hybrid structures, causing 
complement activation. Thus, it would important to verify if they have a 
possible involvement in accelerating of de-myelination process. 
Another interesting feature of the myelin N-linked structure is the 
significant presence of sulfated structures. The presence of sulfate is 
essential for myelin function. Indeed, knock-out mice for GlcNAc6ST-1 
sulfotransferase show loss of myelin compaction and axonal degeneration 
(Yoshimura et al. 2017). The important role of negative charges in myelin 
N-linked glycans is also highlighted by the presence of sialic acid. In other 
species, including humans, the presence of negative charges is also ensured 
by the HNK-1 epitope, which is characterized by the presence of both 
glucuronic acid and sulfate (Löw K. et al. 1994). It is interesting to note that 
the HNK-1 is the antigen recognized by auto-antibodies in acquired human 
neuropathies, highlighting also the importance of glycans to promote 
immune activation against myelin in some types of human 
neurodegenerative diseases (Burger D et al. 1992). 
O-linked glycans were not found in our analysis. This is consistent with 
previous data, which did not report their presence in large amounts, at least 
in compact myelin. However, it is not possible to exclude that they could be 
present in very low amounts.  Moreover, analysis of O-linked glycans is 
more technically challenging. The first one is that glycan release need to be 
done using a chemical method and not an enzymatic one. PNGase, which is 
used to release N-linked glycan from the Asn, is a very active enzyme that 
works well in most experimental conditions, even in the presence of 
moderate detergent concentrations or high salts. On the other hand, O-
glycosidases, which release the glycans from the Ser o Thr residues, are 
available, but have a very restrictive specificity and their activity is quite 
low. For this reason, a chemical method, β-elimination in the alkaline 
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conditions in the presence of reducing agents is the preferred method (North 
SJ et al. 2010). However, this procedure can lead to damage of the glycan 
structure, the so-called “peeling” reaction, thus affecting glycan recovery. 
For this reason, analysis of O-linked glycans should be performed using 
very large amounts of starting material. 
Finally, this procedure could be also applied to the analysis of 
glycolipids. Indeed, after myelin purification, the following step is 
represented by a modified Folch extraction. With this method, all the 
phospholipids and sphingolipids are supposed to be extracted in the organic 
phase. Analysis of the lipid fraction was beyond the scope of this study. 
However, it is important to keep in mind that glycolipids can have also 
profound effects on myelin function. 
In conclusion, the methods optimised in our laboratories have been 
demonstrated to be highly sensitive and reproducible and, together with our 
data, may be a starting point to understand the importance of myelin in the 
glycosylation of the PNS. 
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Supplemental tables and figures 
 
 
Protein Peptide Label Start End 
Myelin Protein P0 YQPEGGR 1:T003 68 74 
Myelin Protein P0 YQPEGGR 1:T003 68 74 
Myelin Protein P0 YQPEGGR 1:T003 68 74 
Myelin Protein P0 YQPEGGR 1:T003 68 74 
Myelin Protein P0 YQPEGGR 1:T003 68 74 
Myelin Protein P0 YQPEGGR 1:T003 68 74 
Myelin Protein P0 YQPEGGR 1:T003 68 74 
Myelin Protein P0 YQPEGGRDAISIFHYAK 1:T003-004 68 84 
Myelin Protein P0 YQPEGGRDAISIFHYAKGQPYI-DEVGAFKERIQWVGDPR 1:T003-007 68 106 
Myelin Protein P0 DAISIFHYAKGQPYIDEVGAFK- ERIQWVGDPRWK 1:T004-008 75 108 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFKER 1:T005-006 85 98 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFKER 1:T005-006 85 98 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 GQPYIDEVGAFK 1:T005 85 96 
Myelin Protein P0 ERIQWVGDPR 1:T006-007 97 106 
Myelin Protein P0 ERIQWVGDPR 1:T006-007 97 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPRWK 1:T007-008 99 108 
Myelin Protein P0 IQWVGDPRWK 1:T007-008 99 108 
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Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPRWK 1:T007-008 99 108 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 IQWVGDPR 1:T007 99 106 
Myelin Protein P0 DGSIVIHNLDYSDNGTFTCDVK 1:T009* 109 130 
Myelin Protein P0 DGSIVIHNLDYSDNGTFTCDVK 1:T009* 109 130 
Myelin Protein P0 NPPDIVGK 1:T010 131 138 
Myelin Protein P0 NPPDIVGK 1:T010 131 138 
Myelin Protein P0 NPPDIVGK 1:T010 131 138 
Myelin Protein P0 TSQVTLYVFEK 1:T011 139 149 
Myelin Protein P0 TSQVTLYVFEK 1:T011 139 149 
Myelin Protein P0 TSQVTLYVFEK 1:T011 139 149 
Myelin Protein P0 VPTR 1:T012 150 153 
Myelin Protein P0 VPTRYGVVLGAVIGGILGVVLL- LLLLFYLIRYCWLRR 1:T012-015* 150 186 
Myelin Protein P0 VPTRYGVVLGAVIGGILGVVLL- LLLLFYLIRYCWLRR 1:T012-015* 150 186 
Myelin Protein P0 VPTR 1:T012 150 153 
Myelin Protein P0 VPTR 1:T012 150 153 
Myelin Protein P0 VPTR 1:T012 150 153 
Myelin Protein P0 VPTR 1:T012 150 153 
Myelin Protein P0 YGVVLGAVIGGILGVVLLLLLLF- YLIRYCWLR 1:T013-014* 154 185 
Myelin Protein P0 YGVVLGAVIGGILGVVLLLLLLF-YLIRYCWLRRQAALQRR 1:T013-017* 154 193 
Myelin Protein P0 YCWLR 1:T014* 181 185 
Myelin Protein P0 YCWLRRQAALQR 1:T014-016* 181 192 
Myelin Protein P0 YCWLRR 1:T014-015* 181 186 
Myelin Protein P0 YCWLRRQAALQRR 1:T014-017* 181 193 
Myelin Protein P0 YCWLR 1:T014* 181 185 
Myelin Protein P0 YCWLRRQAALQR 1:T014-016* 181 192 
Myelin Protein P0 YCWLR 1:T014* 181 185 
Myelin Protein P0 YCWLRR 1:T014-015* 181 186 
Myelin Protein P0 YCWLR 1:T014* 181 185 
Myelin Protein P0 R 1:T015 186 186 
Myelin Protein P0 RQAALQRRLSAMEK 1:T015-018 186 199 
Myelin Protein P0 QAALQRR 1:T016-017 187 193 
Myelin Protein P0 QAALQRR 1:T016-017 187 193 
Myelin Protein P0 QAALQRR 1:T016-017 187 193 
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Myelin Protein P0 QAALQRR 1:T016-017 187 193 
Myelin Protein P0 QAALQRR 1:T016-017 187 193 
Myelin Protein P0 QAALQRR 1:T016-017 187 193 
Myelin Protein P0 QAALQRR 1:T016-017 187 193 
Myelin Protein P0 RLSAMEK 1:T017-018 193 199 
Myelin Protein P0 RLSAMEK 1:T017-018 193 199 
Myelin Protein P0 RLSAMEK 1:T017-018 193 199 
Myelin Protein P0 RLSAMEK 1:T017-018 193 199 
Myelin Protein P0 RLSAMEK 1:T017-018 193 199 
Myelin Protein P0 RLSAMEKGRFHK 1:T017-020 193 204 
Myelin Protein P0 RLSAMEKGR 1:T017-019 193 201 
Myelin Protein P0 LSAMEK 1:T018 194 199 
Myelin Protein P0 LSAMEKGRFHK 1:T018-020 194 204 
Myelin Protein P0 LSAMEKGRFHK 1:T018-020 194 204 
Myelin Protein P0 LSAMEKGRFHKSSK 1:T018-021 194 207 
Myelin Protein P0 LSAMEKGR 1:T018-019 194 201 
Myelin Protein P0 LSAMEKGRFHK 1:T018-020 194 204 
Myelin Protein P0 FHK 1:T020 202 204 
Myelin Protein P0 FHK 1:T020 202 204 
Myelin Protein P0 FHKSSKDSSK 1:T020-022 202 211 
Myelin Protein P0 FHKSSKDSSK 1:T020-022 202 211 
Myelin Protein P0 FHKSSKDSSK 1:T020-022 202 211 
Myelin Protein P0 FHKSSKDSSKR 1:T020-023 202 212 
Myelin Protein P0 FHKSSKDSSKR 1:T020-023 202 212 
Myelin Protein P0 FHK 1:T020 202 204 
Myelin Protein P0 FHKSSKDSSKR 1:T020-023 202 212 
Myelin Protein P0 FHKSSKDSSKRGR 1:T020-024 202 214 
Myelin Protein P0 SSKDSSKR 1:T021-023 205 212 
Myelin Protein P0 SSKDSSK 1:T021-022 205 211 
Myelin Protein P0 SSKDSSKR 1:T021-023 205 212 
Myelin Protein P0 SSKDSSKR 1:T021-023 205 212 
Myelin Protein P0 SSKDSSKR 1:T021-023 205 212 
Myelin Protein P0 SSKDSSKR 1:T021-023 205 212 
Myelin Protein P0 SSKDSSKRGR 1:T021-024 205 214 
Myelin Protein P0 DSSKRGR 1:T022-024 208 214 
Myelin Protein P0 DSSKR 1:T022-023 208 212 
Myelin Protein P0 DSSK 1:T022 208 211 
Myelin Protein P0 DSSKRGR 1:T022-024 208 214 
Myelin Protein P0 GRQTPVLYAMLDHSRSTK 1:T024-026 213 230 
Myelin Protein P0 GRQTPVLYAMLDHSRSTK 1:T024-026 213 230 
Myelin Protein P0 GRQTPVLYAMLDHSR 1:T024-025 213 227 
Myelin Protein P0 STKAASEK 1:T026-027 228 235 
Myelin Protein P0 STKAASEK 1:T026-027 228 235 
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Myelin Protein P0 STKAASEKK 1:T026-028 228 236 
Myelin Protein P0 STKAASEK 1:T026-027 228 235 
Myelin Protein P0 AASEKK 1:T027-028 231 236 
Myelin Protein P0 AASEKK 1:T027-028 231 236 
Myelin Protein P0 AASEKK 1:T027-028 231 236 
Myelin Protein P0 AASEK 1:T027 231 235 
Myelin Protein P0 AASEKKSK 1:T027-029 231 238 
Myelin Protein P0 AASEKKSKGLGESR 1:T027-030 231 244 
Myelin Protein P0 K 1:T028 236 236 
Myelin Protein P0 GLGESR 1:T030 239 244 
Myelin Protein P0 GLGESRK 1:T030-031 239 245 
Myelin Protein P0 GLGESRK 1:T030-031 239 245 
Myelin Protein P0 GLGESR 1:T030 239 244 
Myelin Protein P0 GLGESRKDK 1:T030-032 239 247 
Myelin Protein P0 GLGESRKDK 1:T030-032 239 247 
Myelin Protein P0 GLGESRKDKK 1:T030-033 239 248 
 
 
ST1. MPZ peptides found in the ESI analysis. 
 
Accession Entry mW (Da) pI (pH) 
PLGS 
Score 
TRYP_PIG TRYP_PIG 24393 6,9141 10794,42 
B2RSN3_MOUSE B2RSN3_MOUSE 49920 4,5908 4638,735 
MYP0_MOUSE MYP0_MOUSE 27604 9,7515 3947,008 
E9QQ57_MOUSE E9QQ57_MOUSE 147536 8,5488 3938,486 
PRAX_MOUSE PRAX_MOUSE 147594 8,3584 3689,903 
F6RT34_MOUSE F6RT34_MOUSE 23182 11,2778 2220,164 
F6TYB7_MOUSE F6TYB7_MOUSE 21167 11,1343 2195,693 
TBA1A_MOUSE TBA1A_MOUSE 50103 4,7622 2008,445 
TBA1B_MOUSE TBA1B_MOUSE 50119 4,7622 1784,487 
TBA4A_MOUSE TBA4A_MOUSE 49892 4,752 1026,153 
ALBU_MOUSE ALBU_MOUSE 68647 5,6763 382,7863 
CD9_MOUSE CD9_MOUSE 25240 6,9639 326,9419 
NDUF3_MOUSE NDUF3_MOUSE 20720 8,0273 270,2818 
AGK_MOUSE AGK_MOUSE 46946 8,4419 211,6779 
A0A140T8I6_MOUSE A0A140T8I6_MOUSE 36076 10,4546 197,3638 
AT1B1_MOUSE AT1B1_MOUSE 35171 8,7817 197,2095 
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ST2. In this table, all the hits for the ESI/MS analysis are reported. 
 
NFL_MOUSE NFL_MOUSE 61471 4,415 195,2418 
A2AHQ7_MOUSE A2AHQ7_MOUSE 133722 5,937 172,1517 
GLT10_MOUSE GLT10_MOUSE 69071 8,417 170,4506 
ISL2_MOUSE ISL2_MOUSE 39702 8,0991 170,4261 
CD69_MOUSE CD69_MOUSE 22502 6,5859 170,1749 
CN37_MOUSE CN37_MOUSE 47093 9,2578 167,2831 
G3UZY9_MOUSE G3UZY9_MOUSE 14026 10,6875 161,5311 
MSL1_MOUSE MSL1_MOUSE 67277 9,2944 155,1338 
A2AP78_MOUSE A2AP78_MOUSE 18299 10,2085 154,8326 
FA10_MOUSE FA10_MOUSE 53983 5,3438 143,0321 
Q6PCM4_MOUSE Q6PCM4_MOUSE 66328 8,8652 142,8326 
A0A0A6YWC8_MOUSE A0A0A6YWC8_MOUSE 49162 4,8618 142,5211 
A2ARR8_MOUSE A2ARR8_MOUSE 39915 9,3896 140,6328 
D3YYX3_MOUSE D3YYX3_MOUSE 17386 8,8403 136,8201 
Q99K53_MOUSE Q99K53_MOUSE 79920 9,7163 133,8669 
A0A0J9YU37_MOUSE A0A0J9YU37_MOUSE 64611 6,1802 133,7945 
GBA2_MOUSE GBA2_MOUSE 103227 5,2192 133,1584 
Q6NV92_MOUSE Q6NV92_MOUSE 75901 9,6313 131,0092 
Q7TMN8_MOUSE Q7TMN8_MOUSE 66999 9,1743 128,6747 
A2ARX1_MOUSE A2ARX1_MOUSE 60276 9,3105 128,23 
TLR8_MOUSE TLR8_MOUSE 119282 6,9199 125,4914 
D3Z5Z2_MOUSE D3Z5Z2_MOUSE 57364 9,3486 123,9828 
RAB6A_MOUSE RAB6A_MOUSE 23574 5,2266 123,8001 
ZFP28_MOUSE ZFP28_MOUSE 93249 9,3472 123,3146 
G3X964_MOUSE G3X964_MOUSE 80229 7,6055 119,3493 
Q8BUQ3_MOUSE Q8BUQ3_MOUSE 97193 9,3164 119,2382 
ALD2_MOUSE ALD2_MOUSE 36097 5,9326 117,9798 
ZFP26_MOUSE ZFP26_MOUSE 97925 8,168 116,8602 
Q8BIB6_MOUSE Q8BIB6_MOUSE 61091 8,9136 116,5319 
Q8BLK6_MOUSE Q8BLK6_MOUSE 66514 8,4888 115,8054 
A2AHM2_MOUSE A2AHM2_MOUSE 34502 9,3457 115,3875 
NFM_MOUSE NFM_MOUSE 95858 4,5571 98,7081 
FRMD8_MOUSE FRMD8_MOUSE 51795 5,9854 89,1637 
Q3U4X8_MOUSE Q3U4X8_MOUSE 104028 6,709 67,0747 
ZC3HD_MOUSE ZC3HD_MOUSE 203633 9,7646 60,9883 
H7BX26_MOUSE H7BX26_MOUSE 173839 6,7544 42,2316 
F8WGF2_MOUSE F8WGF2_MOUSE 164210 6,8291 33,9826 
D3YVU4_MOUSE D3YVU4_MOUSE 144760 8,1372 33,4279 
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Molecular ions  
[M + Na]+ 
Structure 
1579.8 GlcNAc2-Man5 
1783.9 GlcNAc2-Man6 
1999.1 GlcNAc3-Man4-Gal-Fuc 
2040.1 GlcNAc4-Man3-Gal-Fuc 
2081.1 GlcNAc5-Man3-Fuc 
2156.1 GlcNAc3-Man3-Gal-Fuc-Neu5Ac 
2244.2 GlcNAc4-Man3-Gal2-Fuc 
2285.2 GlcNAc5-Man3-Gal-Fuc 
2360.3 GlcNAc3-Man4-Gal-Fuc-NeuAc 
2390.3 GlcNAc3-Man4-Gal-Fuc-NeuGc 
2448.3 GlcNAc4-Man3-Gal3-Fuc 
2564.4 GlcNAc3-Man5-Gal-Fuc-NeuAc 
2594.4 GlcNAc3-Man5-Gal-Fuc-NeuGl 
2605.3 GlcNAc4-Man3-Gal2-Fuc-NeuAc 
2646.4 GlcNAc5-Man3-Gal-NeuAc 
2722.4 GlcNAc3-Man4-Gal-Fuc-NeuAc2 
2809.5 GlcNAc4-Man3-Gal3-Fuc-NeuAc 
2839.5 GlcNAc4-Man3-Gal3-Fuc-NeuGc 
2966.6 GlcNAc4-Man3-Gal2-Fuc-NeuAc2 
2996.6 GlcNAc4-Man3-Gal2-Fuc-NeuAc-NeuGc 
3013.6 GlcNAc4-Man4-Gal3-Fuc-NeuAc 
3054.6 GlcNAc5-Man3-Gal3-Fuc-NeuAc 
 
 
Table ST3. Neutral permethylated N-glycans found in positive ion mode 
analysis. 
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Molecular ions 
[M + (n+1)Na-nH]+ 
(n = number of sulfated 
group) 
Structure 
1986.0 GlcNAc3-Hex5-Fuc-S 
2072.9 GlcNAc3-Man4-Gal-Fuc 
2086.9 GlcNAc3-Man4-Gal-Fuc-S 
2252,9 GlcNAc3-Man3-Gal-Fuc-NeuAc-S 
2369.1 GlcNAc3-Man4-Gal-Fuc-NeuAc 
2399,1 GlcNAc3-Man4-Gal-Fuc-NeuGc 
2456.0 GlcNAc3-Man4-Gal-NeuAc-S 
2486.1 GlcNAc3-Man4-Gal-Fuc-NeuGc-S 
2498.1 GlcNAc4-Man3-Gal-NeuAC-(S) 
2573.2 GlcNAc3-Man5-Gal-Fuc-NeuAc 
2661.1 GlcNAc3-Man5-Gal-Fuc-NeuAc-S 
2702.1 GlcNAc4-Man3-Gal2-Fuc-NeuAc-S 
2818.3 GlcNAc3-Man4-Gal-Fuc-NeuAc2-S 
3071.2 GlcNAc4-Man3-Gal2-Fuc-NeuAc2-S 
 
 
Table ST4. Polar permethylated N-glycans found in positive ion mode 
analysis. 
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Molecular ions 
[M-H]- 
Structure 
1823.9 GlcNAc3-Hex5-Fuc-S 
2027.0 GlcNAc3-Man4-Gal-Fuc 
2041.1 GlcNAc3-Man4-Gal-Fuc-S 
2206,1 GlcNAc3-Man3-Gal-Fuc-NeuAc-S 
2411.1 GlcNAc3-Man4-Gal-NeuAc-S 
2440.1 GlcNAc3-Man4-Gal-Fuc-NeuGc-S 
2615.2 GlcNAc3-Man5-Gal-Fuc-NeuAc-S 
2655.3 GlcNAc4-Man3-Gal2-Fuc-NeuAc-S 
3024.4 GlcNAc4-Man3-Gal2-Fuc-NeuAc2-S 
 
Table ST5. Polar permethylated N-glycans found in negative ion mode 
analysis. 
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SF1. MS/MS spectra showing the modified weight of fragments caused 
by incomplete permethylation of the sialic acids. 
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SF2. This image shows the metabolism of complex glycans from a high 
mannose. (Daniel Chui et al. 2001)  
